Home       Extracts       Products       Symptoms       FAQs
News

Hop-on Subsidiary Re-Medical Seeks Licensing of Cannabis Transdermal Delivery Innovations

February 28, 2017 13:20 ET

TEMECULA, CA--(Marketwired - Feb 28, 2017) - Hop-on, Inc. (OTC PINK: HPNN) announced today its subsidiary, Re-Medical, Inc., is setting up distribution of cannabis transdermal patches in legal jurisdictions.

Re-Medical is actively pursuing opportunities for production and distribution of the Company's various innovative products for the transdermal delivery of standardized cannabinoid formulations. Partnerships, technology licensing agreements, and distribution contracts are being offered to locally authorized marijuana cultivators, producers of infused products, and medical marijuana dispensaries in California, Colorado, Washington, Nevada, and other self-regulated markets in the United States.

Re-Medical's mission is to provide solutions for patients desiring to use cannabis as a nutraceutical alternative to traditional or prescription medications.

Re-Medical is a Hop-on company focused on alternative ways to deliver vitamins, supplements and other healthful products such as cannabis, utilizing transdermal patches and other novel technologies. The company has developed and isolated the benefits of cannabis and other vital plant extracts for best patient care. There are an estimated 80+ cannabinoids found in cannabis, each providing distinctive neuropathic effects. The company is currently applying for patents regarding the delivery of cannabis via transdermal patches. Re-Medical patches offer cost effective, accurate and clean delivery of these unique compounds.

Hop-on, Inc. (OTC PINK: HPNN) is a global ODM and OEM manufacturer of electronics, based in the United States. Over the past 20 years, Hop-on has successfully secured essential patents for mobile communications and computing technologies, and is respected for developing the world's first disposable cell phone. Hop-on's focus on smartphones and innovative mobile device applications is bringing cost friendly solutions to today's demanding world market. Hop-on is also diversified in delivering cannabis remedies. For more information, please visit www.re-medical.com

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Copyright © 2017 Re-Medical, Inc., a wholly owned subsidiary of Hop-on, Inc. (OTC PINK: HPNN) Terms of Use
All rights reserved. Reproduction of any information contained in this site for commercial purposes is strictly prohibited.

The products and statements made about specific products on this web site have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on this web site or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional.

Re-Medical, Inc. provides a topical patch that uses some aspects related to the regulated cannabis industry. Re-Medical, Inc. does not grow, harvest, distribute or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor do they intend to do so in the future. As of March 21, 2014, twenty states and the District of Columbia allow its citizens to use Medical Marijuana and voters in the states of Colorado and Washington approved ballot measures to legalize cannabis for adult use. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial changes to the Company. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.